Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users

Psychopharmacology

Volumn 233, Issue 13, 2016, Pages 2469-2478

  Herrmann, Evan S ^a   Cooper, Ziva D ^a   Bedi, Gillinder ^a   Ramesh, Divya ^a   Reed, Stephanie C ^a   Comer, Sandra D ^a   Foltin, Richard W ^a   Haney, Margaret ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cannabinoids; Relapse; Self administration; Withdrawal

Indexed keywords

CANNABIS; NABILONE; PLACEBO; ZOLPIDEM; ANXIOLYTIC AGENT; DRONABINOL; HYPNOTIC SEDATIVE AGENT; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANNABIS ADDICTION; CLINICAL ARTICLE; COGNITION; DRUG EFFECT; FEMALE; FOOD INTAKE; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; SLEEP DISORDER; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; AFFECT; ANALOGS AND DERIVATIVES; CANNABIS SMOKING; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EATING; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; SLEEP; YOUNG ADULT;

ADULT; AFFECT; ANTI-ANXIETY AGENTS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRONABINOL; DRUG THERAPY, COMBINATION; EATING; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MARIJUANA ABUSE; MARIJUANA SMOKING; MIDDLE AGED; PYRIDINES; SLEEP; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84963716747     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4298-6     Document Type: Article

References (46)

1. Allsop DJ, Copeland J, Norberg MM, Fu S, Molnar A, Lewis J et al (2012) Quantifying the clinical significance of cannabis withdrawal. PLoS ONE 7, e44864. doi:10.1371/journal.pone.0044864
2. Balter RE, Cooper ZD, Haney M (2014) Novel pharmacologic approaches to treating cannabis use disorder. Curr Addict Rep 1:137–143
3. Bedi G, Foltin RW, Gunderson EW, Rabkin J, Hart CL, Comer SD et al (2010) Efficacy and tolerability of high-dose dronabinol maintenance in HIV-positive marijuana smokers: a controlled laboratory study. Psychopharmacology 212:675–686
4. Bedi G, Cooper ZD, Haney M (2013) Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol 18:872–881
5. Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychol 112:393–402
6. Budney AJ, Hughes JR, Moore BA, Vandrey R (2004) Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 161:1967–1977
7. Budney AJ, Moore BA, Rocha HL, Higgins ST (2006) Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. J Consult Clin Psychol 74:307–316
8. Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B (2007) Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 86:22–29
9. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z (2008) Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 35:362–368
10. Carroll KM, Nich C, LaPaglia DM, Peters EN, Easton CJ, Petry NM (2012) Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less. Addiction 107:1650–1659
11. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M (2013) A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol 18:993–1002
12. Evans SM, Foltin RW, Levin FR, Fischman MW (1995) Behavioral and subjective effects of DN-2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 6:176–186
13. Foltin RW, Fischman MW, Pedroso JJ, Pearlson GD (1987) Marijuana and cocaine interactions in humans: cardiovascular consequences. Pharmacol Biochem Behav 28:459–464
14. Foltin RW, Haney M, Comer SD, Fischman MW (1996) Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Physiol Behav 59:295–305
15. Fraser AD, Meatherall R (1989) Lack of interference by nabilone in the EMIT® dau cannabinoid assay, Abbott TDx® cannabinoid assay, and a sensitive TLC assay for Δ9-THC-carboxylic acid. J Anal Toxicol 13:240
16. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW (1981) Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 21:383S–396S
17. Gorelick DA, Goodwin RS, Schwilke E, Schwope DM, Darwin WD, Kelly DL et al (2013) Tolerance to effects of high-dose oral Δ9-tetrahydrocannabinol and plasma cannabinoid concentrations in male daily cannabis smokers. J Anal Toxicol 37:11–16
18. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W (2003) Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction 98:1371–1378
19. Haney M (2005) The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatr Rep 7:360–366
20. Haney M (2009) Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict Biol 14:9–21
21. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385–394
22. Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW (2004) Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 29:158–170
23. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW (2008) Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 197:157–168
24. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW (2010) Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 211(2):233–244
25. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW (2013a) Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology 38:1557–1565
26. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW (2013b) Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry 73:242–248
27. Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW (2002) Effects of oral THC maintenance on smoked marijuana self-administration. Drug Alcohol Depend 67:301–309
28. Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H et al (2015) Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 72:1–9
29. Kouri EM, Pope HG Jr (2000) Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 8:483–492
30. Krystal AD, Erman M, Zammi GK, Soubrane C, Roth T (2008) Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep 31:79–90
31. Lemberger L, Rubin A, Wolen R, DeSante K, Rowe H, Forney R et al (1982) Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 9:17–23
32. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV (2011) Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend 116:142–150
33. Lile JA, Kelly TH, Hays LR (2010) Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating δ9-tetrahydrocannabinol. Clin Neuropharmacol 33:235–242
34. Lile JA, Kelly TH, Hays LR (2011) Separate and combined effects of the cannabinoid agonists nabilone and Δ 9-THC in humans discriminating Δ 9-THC. Drug Alcohol Depend 116:86–92
35. Mendelson JH, Mello NK (1984) Reinforcing properties of oral Δ 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 83:351–356
36. Randall S, Roehrs TA, Roth T (2012) Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep 35:1551–1557
37. Roehrs TA, Randall S, Harris E, Maan R, Roth T (2012) Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study. J Psychopharmacol 26(8):1088–1095
38. Rush CR, Baker RW, Wright K (1999) Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans. Psychopharmacology 144:220–233
39. Scharf MB, Rot T, Vogel GW, Walsh JK (1994) A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55:192–199
40. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2014) Treatment Episode Data Set (TEDS): 2002–2012. National Admissions to Substance Abuse Treatment Services. BHSIS Series S-71, HHS Publication No. (SMA) 14–4850. Rockville, MD
41. Vandrey RG, Budney AJ, Hughes JR, Liguori A (2008) A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 92:48–54
42. Vandrey R, Smith M, McCann UD, Budney AJ, Curran EM (2011) Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 117:38–44
43. Vandrey R, Stitzer ML, Mintzer MZ, Huestis MA, Murray JA, Lee D (2013) The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. Drug Alcohol Depend 128:64–70
44. Volkow ND, Baler RD, Compton WM, Weiss SR (2014) Adverse health effects of marijuana use. N Engl J Med 370:2219–2227
45. Ware MA, Arnaud‐Trempe S (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494–503
46. World Health Organization (n.d.) Management of substance abuse: cannabis. Retrieved from http://www.who.int/substance_abuse/facts/cannabis/en/